Heart failure & cardiomyopathiesCohort study
Clinical Application of Guideline-Directed Medical Therapy in Transcatheter Aortic Valve Replacement (TAVR) Patients With Heart Failure and Reduced Ejection Fraction
- Prospective registry study
- consecutive patients
- Median follow-up 699 days (Q1-Q3: 510-961 days)
Authors' conclusion
HF-GDMT is underused in patients with HFrEF who undergo TAVR, and suboptimal HF-GDMT is associated with increased MACE in this setting.
Study context
- Population
- TAVR patients with HF with reduced ejection fraction (HFrEF)
- Participants
- 336 patients
- Exposure
- Quadruple vs triple vs double vs single or no HF-GDMT
- Outcome
- Major adverse cardiovascular events (MACE):
- CV mortality
- Heart failure (HF) hospitalization
- Follow-up
- 2 years, after a 3-month HF-GDMT optimization period
Main finding
As reported in the abstract
2-year MACE by HF-GDMT at 3 months · 2 years
P < 0.001
Observational data: associations, not effects.
Further findings
HF-GDMT use at discharge and at 3 months
Discharge
3 months
- HF-GDMT use at discharge and at 3 months — Eligible for quadruple HF-GDMT: 280 (83.3%); received it at 3 months
- 27% (n = 76)
Original publication
Clinical Application of Guideline-Directed Medical Therapy in TAVR Patients With Heart Failure and Reduced Ejection Fraction. JACC Cardiovasc Interv. Published 12 January 2026. doi:10.1016/j.jcin.2025.10.050
Summarised from the published abstract; every number is checked against it